Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

7.1%

2 terminated/withdrawn out of 28 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

N/A

14(53.8%)

Phase 1

9(34.6%)

Early Phase 1

3(11.5%)

26Total

N/A(14)

Phase 1(9)

Early Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (28)

Showing 20 of 28 trials

NCT06895811Phase 1Active Not Recruiting

Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC

Role: collaborator

NCT06228404Early Phase 1Active Not Recruiting

Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC

Role: collaborator

NCT05577312Phase 1Enrolling By Invitation

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Role: lead

NCT07248176Not ApplicableRecruiting

Universal CAR-T Cell Therapy for MM

Role: lead

NCT07248163Not ApplicableRecruiting

Universal CAR-T Cell Therapy for NHL

Role: lead

NCT05741359Phase 1Recruiting

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Role: lead

NCT06485232Early Phase 1Not Yet Recruiting

Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.

Role: collaborator

NCT05859997Not ApplicableEnrolling By Invitation

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

Role: lead

NCT06633042Phase 1Not Yet Recruiting

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

Role: lead

NCT06681337Early Phase 1Not Yet Recruiting

Universal CAR-T Cell Therapy for Refractory Lupus Nephritis

Role: lead

NCT05988216Not ApplicableRecruiting

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Role: lead

NCT06300723Not ApplicableEnrolling By Invitation

Clinical Study of BRL-101 in Severe SCD

Role: lead

NCT06287086Not ApplicableNot Yet Recruiting

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

Role: lead

NCT06298630Not Yet Recruiting

Long-term Follow-up Study of BRL-101 for TDT

Role: lead

NCT06287099Not ApplicableNot Yet Recruiting

Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease

Role: lead

NCT06314529Recruiting

Long-term Follow-up Study of BHC001 for TDT

Role: lead

NCT05442346Not ApplicableSuspended

Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

Role: lead

NCT04211480Not ApplicableCompleted

Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

Role: lead

NCT05308875Not ApplicableUnknown

Efficacy and Safety Evaluation of PD1-BCMA-CART

Role: lead

NCT04213469Not ApplicableCompleted

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

Role: lead